.jpg)
1 hour ago
3
Article content
TORONTO, June 04, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the 2026 American Diabetes Association Thought Leadership Series at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
The Thought Leadership Film Series is a curated set of films profiling organizations active in research and innovation across the field. The series is designed to increase visibility for groups working to prevent and treat diabetes and to improve the lives of people affected by the disease.
Article content
Article content
Article content
The film “Advancing Therapies for Diabetic Kidney Disease,” profiles the pioneering work at Arch Biopartners to build kidney therapeutics that addresses diabetic kidney disease (DKD) through new biology, including recent data published in Inflammation Research identifying IL-32 as a lipid droplet-associated cytokine linked to tubular injury in diabetic kidneys.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
During the conference, the film will also be available online on the American Diabetes Association Scientific Sessions website: https://professional.diabetes.org/scientific-sessions. If you are not attending the conference, you can also watch the full 2026 ADA Thought Leadership Series playlist. You can also view “Advancing Therapies for Diabetic Kidney Disease” directly on YouTube here: https://youtu.be/S9CppOv643s.
Article content
About Arch Biopartners
Article content
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.
Article content
Article content
Arch’s development pipeline includes:
Article content
- LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI.
- Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI.
- CKD Platform: next-generation therapeutics targeting chronic kidney disease.
Article content
These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide.1 Both Phase II programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development.
Article content
For more details about the Company’s science and ongoing clinical trials, please visit www.archbiopartners.com/our-science
Article content
Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for company updates and scientific content.
Article content
The Company has 67,933,289 common shares outstanding.
Article content
For more information, please contact:
Article content
Aaron Benson
Director of Communications
Arch Biopartners, Inc.
647-428-7031
English (US)